This activity is supported by an educational grant from Novo Nordisk.
This program is intended for NPs and PAs who care for patients with T2D.
Describe the mechanism and clinical utility of GLP-1 RA therapy in patients with T2D
Differentiate among the GLP-1 RAs based on their glycemic effects, weight loss, and cardiorenal risk reduction
Incorporate GLP-1 RAs as part of guideline-recommended care based on patientsâ cardiovascular, renal, and other risk factors
Formulate strategies to prevent and minimize gastrointestinal adverse effects of GLP-1 RAs, including dose titration and counseling
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Maria Argoud, PA-C: consultant/advisor/speaker: Zealand.
Darren K. McGuire, MD, MHSc: consultant: Afimmune, Applied Therapeutics, Bayer, Metavant; clinical trial leader: AstraZeneca, Esperion, Lexicon, Pfizer; consultant/clinical trial leader: Boehringer Ingelheim, CSL Behring, Lilly, Merck, Novo Nordisk, Sanofi.
Richard E. Pratley, MD: researcher: Metavention, Poxel SA; consultant/advisor/speaker: Bayer, Corcept Therapeutics, Dexcom, Gasherbrum Bio, Hengrui USA, Merck, Pfizer, Rivus Pharmaceuticals, Sanofi, Scohia Pharma, Sun Pharmaceuticals; researcher/consultant/advisor/speaker: Hanmi Pharmaceuticals, Novo Nordisk.
Laura Ross, PA-C: has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any financial relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
The estimated time to complete this activity is 1.50 hours.
Release date: July 15, 2022
Expiration date: July 14, 2023
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP Planner: Mary Knudtson, DNSc, NP, FAAN, University of California, Irvine, Irvine, California
Nursing contact hours: 1.50, which includes 1.50 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until July 14, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Amanda Zimmerman, PA-C, West Forsyth Pain Management, Winston-Salem, North Carolina
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credits for learning and change.
This program has been made available online.